Despite J&J’s Woes, Wall Street Sees Turnaround In Pharma Business
Executive Summary
Johnson & Johnson’s pharma business appears to be weathering headwinds that are hobbling its consumer and medical device sales. Pharma accounted for 36% of JNJ’s 2010 sales of $61.6 billion.
You may also be interested in...
Zytiga Cleared Fast In Refractory CRPC, Can It Also Move To Earlier Use?
J&J's abiraterone is cleared for use two months ahead of schedule. Pricing of $5,000 a month is much lower than Dendreon's Provenge, approved for earlier stage disease.
Merck And J&J Settle Remicade Dispute By Redrawing The Map
Johnson & Johnson Inc. and Merck & Co. Inc. settled their two-year dispute over Remicade (infliximab) and its successor Simponi (golimumab) April 15, avoiding an arbitrator's decision by striking a revised agreement under which each will retain some territorial rights to the drugs
Sanofi's Cabazitaxel Swiftly Approved, But Launch Date Is Uncertain
Price of next-generation chemotherapy for prostate cancer will be in line with 14 years of development and value to patients, says Sanofi.